Article

Nivolumab and Ipilimumab in Metastatic Melanoma Are Associated with Distinct Immune Landscape Changes and Response-Associated Immunophenotypes

2020-01-16

Abstract excerpt

The reshaping of the immune landscape by nivolumab (NIVO) and ipilimumab (IPI) and its relation to patient outcomes is not well-described. We used high-parameter flow cytometry and a novel computational platform, CytoBrute, to define immunophenotypes of up to 15 markers to assess peripheral blood samples from metastatic melanoma patients receiving sequential NIVO>IPI or IPI>NIVO. The two treatments were associated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c23af9c1-75d5-543b-9585-d0c142de42b9
DOI: 10.1101/2020.01.13.905430

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nivolumab and Ipilimumab in Metastatic Melanoma Are Associated with Distinct Immune Landscape Changes and Response-Associated ImmunophenotypesDOI 10.1101/2020.01.13.905430Read

High IGKC Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint BlockadeSemantic proximity Read

Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in MelanomaSemantic proximity Read

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanomaSemantic proximity Read

Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironmentSemantic proximity Read

Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanomaSemantic proximity Read

Construction of immune scores to predict patient prognosis and response of anti-PD1 treatment in stage III-IV melanomaSemantic proximity Read

Identification of an Immune-Related Prognostic Signature Associated with Immune Infiltration in MelanomaSemantic proximity Read

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanomaSemantic proximity Read

Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic cutaneous melanomaSemantic proximity Read

Predicting response and resistance to immune checkpoint blockade and surgery in melanoma patientsSemantic proximity Read

Tumor Immune Cell Infiltration Patterns and Predictable Clinical Benefit with Nivolumab in Combination with Ipilimumab for 3P ImplementationSemantic proximity Read